Biologics in inflammatory disease: infliximab associated risk of lymphoma development.
Bucher
C
C
Degen
L
L
Dirnhofer
S
S
Pless
M
M
Herrmann
R
R
Schraml
P
P
Went
P
P
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab